American College Of Rheumatology

The American College of Rheumatology has released three new vasculitis treatment guidelines — for ANCA-associated vasculitis, giant cell arteritis and Takayasu arteritis, and polyarteritis nodosa — with a fourth expected soon.

The Alliance for Transparent & Affordable Prescriptions, the Community Oncology Alliance and American Pharmacies have filed an amicus brief in support of efforts in North Dakota to regulate pharmacy benefit managers.

A study of 65 clinical practice guidelines and recommendations from the American College of Rheumatology and EULAR show a lack of clarity regarding race information, and an “urgent need” for standardized race reporting, researchers wrote.

The American College of Rheumatology has released an updated position statement declaring biologic infusions should be administered in a monitored health care setting rather than in the patient’s home, as some insurers have mandated.

The AMA has adopted a new policy that discourages health insurance companies from offering financial incentives to patients for switching medications, according to the organization.

The American College of Rheumatology released its updated 2021 guidelines, which includes 44 recommendations on rheumatoid arthritis. A review of the recommendations was the top story in rheumatology last week.

The American College of Rheumatology has released its updated treatment guidelines for rheumatoid arthritis, with a strong emphasis on the use of methotrexate before adding or switching to DMARDs, according to the lead author.

While certain rheumatology drugs are associated with increased hospitalizations in COVID-19, individuals with rheumatologic diseases largely experience outcomes comparable to general population, according to a presenter at the Biologic Therapies Summit.

The recent explosion in the use of telehealth may compensate for ongoing trends in rheumatology — such as a worsening workforce shortage and rising patient costs — that stifle access to care, according to the American College of Rheumatology.

Despite strong biomarkers and an improved understanding of the many systems involved in IgG4 disease, no curative therapy exists, according to a speaker at the virtual American College of Rheumatology State-of-the-Art Clinical Symposium.